AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!
Issue link: https://eguideline.guidelinecentral.com/i/1512419
Disclaimer is resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers aer consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary. Source Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, Altieri MM, Bansal N, Bello NA, Bress AP, Carter J, Cohen JB, Collins KJ, Commodore-Mensah Y, Davis LL, Egan B, Khan SS, Lloyd-Jones DM, Melnyk BM, Mistry EA, Ogunniyi MO, Schott SL, Smith Jr SC, Talbot AW, Vongpatanasin W, Watson KE, Whelton PK, Williamson JD. 2025 AHA/ACC/AANP/AAPA/ ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiolog y/American Heart Association Joint Committee on Clinical Practice Guidelines. [published online ahead of print August 14, 2025]. J Am Coll Cardiol. doi: 10.1016/j.jacc.2025.05.007. Copublished in Circulation. doi: 10.1161/CIR.0000000000001356. ACCHBP07253a TEL: 407.878.7606 Order additional copies at GuidelineCentral.com Copyright © 2025 All rights reserved GuidelineCentral.com Abbreviations ABPM, ambulatory blood pressure monitoring ; ACE, angiotensin-converting enzyme; ACEi, angiotensin-converting enzyme inhibitor; ACOG, American College of Obstetricians and Gynecologists; ADHD, attention-deficit/hyperactivity disorder; AF, atrial fibrillation; AKI, acute kidney injury; ARB, angiotensin receptor blocker; ARNi, angiotensin receptor-neprilysin inhibitor; ASCVD, atherosclerotic cardiovascular disease; BB, beta blocker; BID, 2 times daily; BMI, body mass index; BP, blood pressure; bpm, beats per minute; CCB, calcium channel blocker; CKD, chronic kidney disease; CHD, coronary heart disease; COR, class of recommendation; CNS, central nervous system; CPAP, continuous positive airway pressure; CT, computed tomography; CVD, cardiovascular disease; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; DOC, 11-deoxycorticosterone; ECG, electrocardiogram; eGFR, estimated glomerular filtration rate; EHR, electronic health record; FDA, Food and Drug Administration; US; GFR, glomerular filtration rate; GDMT, guideline-directed medical therapy; GLP-1RA, glucagon-like peptide-1 receptor agonist; h, hour; HBPM, home blood pressure monitoring ; HCTZ, hydrochlorothiazide; HDL, high-density lipoprotein; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; HbA1c, hemoglobin A1c; HIT, health information technolog y; HTN, hypertension; hr, hours; ICH, intracerebral hemorrhage; IGF-1, insulin-like growth factor-1; IM, intramuscular; IUD, intrauterine device; IV, intravenous; K+, potassium; LOE, level of evidence; LV, le ventricular; MAO, monoamine oxidase; MAOI, monoamine-oxidase inhibitors; MDPV, methylenedioxy pyrovalerone; MI, myocardial infarction; min, minutes; MOA, mechanisms of action; MRA, mineralocorticoid receptor antagonist; NH, non-Hispanic; NYHA, New York Heart Association; NSAIDs, nonsteroidal anti-inflammatory drugs; OH, hydroxylase; OSA, obstructive sleep apnea; PDE-5, phosphodiesterase type-5; P-gp, P-glycoprotein; PREVENT, Predicting Risk of cardiovascular EVENTs; qd, daily; RAS, renin-angiotensin system; RAASi, renin-angiotensin-aldosterone system inhibitor; RCT, randomized controlled trial; RDN, renal denervation; SBP, systolic blood pressure; SDOH, social determinants of health; SGLT2i, sodium-glucose cotransporter-2 inhibitor; SPC, single pill combinations; T2D, type 2 diabetes; TIA, transient ischemic attack; TOD, target organ damage; US, United States; VEGF, vascular endothelial growth factor